Here's a puzzle for you: A biotech company announces promising clinical trial results and gets a regulatory stamp of approval from the FDA. The stock promptly falls nearly 17%. Welcome to the sometimes bewildering world of biotech investing.
On Tuesday, Senti Biosciences, Inc. (SNTI) shared new data from its ongoing trial of SENTI-202, described as a first-in-class CD33/FLT3 targeting Logic Gated CAR NK cell therapy. The treatment targets patients with relapsed or refractory Acute Myeloid Leukemia, which is about as serious as cancer gets—these are patients whose disease has come back or never responded to initial treatment.
The company presented data from 20 patients (18 with evaluable responses) at the American Society of Hematology Annual Meeting. On the same day, the FDA granted the therapy Regenerative Medicine Advanced Therapy designation, a status that can accelerate development and review timelines.
What the Data Actually Shows
The numbers look reasonably encouraging for an early-stage trial. Half of the patients who received the Recommended Phase 2 Dose achieved an Overall Response Rate outcome—meaning the treatment actually worked. Looking at the full trial population, 50% of all patients (9 out of 18) responded.
Even better, 42% of patients at the recommended dose achieved Complete Remission or Complete Remission with Partial Hematologic Recovery. Across all patients, that figure was 39% (7 out of 18). All complete remissions and more than 80% of all responses showed no minimal residual disease—essentially, the cancer became undetectable.
The durability looks promising too. The median duration of composite Complete Remissions across all patients hit 7.6 months based on Kaplan-Meier estimates. One patient maintained a response for over a year and counting as of the data cutoff date.
The safety profile appears clean. No dose-limiting toxicities, no serious adverse events related to SENTI-202, and no patients discontinued treatment due to side effects. The therapy was detected in all patients' peripheral blood and behaved consistently with other allogeneic NK cell therapies—expanding for two weeks before naturally clearing out.
Pharmacodynamic data validated the therapy's OR/NOT Logic Gate mechanism, which is designed to selectively kill leukemia cells and leukemic stem cells while sparing healthy blood-forming stem and progenitor cells. That's the whole ballgame with cancer therapy: kill the bad cells, spare the good ones.
So Why Did the Stock Fall?
That's the question investors are asking. The clinical data suggests the therapy is working in a heavily pretreated patient population—these aren't easy-to-treat patients. The FDA designation provides regulatory momentum. Yet Senti Biosciences shares closed down 16.73% at $1.99 on Tuesday.
Sometimes positive clinical news gets baked into biotech stocks ahead of official announcements. Other times, investors scrutinize the fine print and see limitations in the data. Or perhaps the market simply expected more. In biotech, the gap between "good news" and "good enough news" can be expensive.
